Omeros shares are plummeting due to the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) reaffirming its negative opinion on narsoplimab for TA-TMA. This definitive rejection significantly diminishes the drug's commercial prospects in Europe, leading to a sharp sell-off for the company.
This is a major negative catalyst for Omeros as the EMA's CHMP has definitively rejected marketing authorization for narsoplimab in TA-TMA, even after re-examination. This decision effectively closes off the European market for this drug, which was a significant part of the company's future revenue projections. The biotechnology sector is highly sensitive to regulatory approvals, and a clear rejection like this can severely impact a company's valuation and future viability, especially for a drug that was considered a key pipeline asset. Investors will likely re-evaluate Omeros's entire pipeline and financial outlook, leading to sustained downward pressure on the stock.